west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "赵敬生" 2 results
  • 超声造影与 MRI 增强扫描在高强度聚焦超声治疗子宫肌瘤中的疗效监测

    目的 比较超声造影(contrast-enhanced ultrasound,CEUS)与 MRI 增强扫描在高强度聚焦超声(high intensive focused ultrasound,HIFU)治疗子宫肌瘤中的疗效监测作用。 方法 选取 2013 年 1 月—2014 年 12 月采用 HIFU 治疗的 179 例子宫肌瘤患者(共 234 个肌瘤),对治疗前肌瘤体积及治疗后非灌注区肌瘤消融体积分别采用 CEUS 和 MRI 增强扫描检查。 结果 CEUS 和 MRI 增强扫描在治疗前肌瘤体积对比中差异有统计学意义(P<0.05),在治疗后非灌注区肌瘤消融体积对比中差异无统计学意义(P>0.05)。对治疗后残留两者均可有效检出。 结论 CEUS 和 MRI 增强扫描在 HIFU 治疗前都是治疗必须的检查,两者不可替代;两者均是治疗后疗效评价的有效方法,但 CEUS 比 MRI 增强扫描在治疗中更具灵活性、可重复性,在一定程度上可替代 MRI 增强扫描。

    Release date:2017-11-24 10:58 Export PDF Favorites Scan
  • Curative Effect Observation on High-intensity Focused Ultrasound Treatment for Uterine Fibroids

    ObjectiveTo probe into the clinical efficacy of high-intensity focused ultrasound (HIFU) alone for uterine fibroids. MethodBetween February 2012 and February 2014, 145 patients with 174 cases of uterine fibroids were treated with HIFU. Before and one day, 6 months, 12 months after treatment, MRI was performed during the follow-up. We analyzed fibroids narrowing rate, adverse reactions, and clinical symptoms improvement after treatment. ResultsSuccessful completion of HIFU ablation was done for all the fibroids. Enhanced MRI examination before and one day after treatment, and MRI plain scanning 6 and 12 months after treatment showed that fibroid volume before treatment was 4.61-419.70 cm3 (median of 56.82 cm3), fibroid volume after treatment was 3.02-578.21 cm3 (median of 56.74 cm3), ablation volume was 2.42-578.21 cm3 (median of 47.84 cm3), and volumetric ablation rate was 24%-100%; there was no statistically significant difference in fibroid volume before and after treatment (P>0.05); fibroid volume 6 months after treatment was 0-264.50 cm3 (median of 22.49 cm3) and was 0-346.02 cm3 (median of 14.81 cm3) 12 months after treatment with a reduction rate of 60.4% and 73.9% on average respectively, and the volume was significantly different between those two time points and before treatment (P<0.05), and between 6 months and 12 months after treatment (P<0.05). The medians of uterine fibroid symptoms (UFS) and quality of life (QOL) scores before ablation were respectively 21.88 and 71.55 points. UFS reduced by 57.1% and 71.4% respectively 6 and 12 months after ablation, and QOL increased by 15.7% and 26.5% at those two time points. Both UFS and QOL 6 and 12 months after treatment were significantly different from that before treatment (P<0.05), and the UFS and QOL difference between 6 months and 12 months after treatment was also significant (P<0.05). As time went on, UFS gradually reduced, while QOL gradually increased. Complication rate was 2.8% with two cases of skin shallow degree-Ⅱ thermal damage, one of lower limb radiation pain, one of urinary retention, and there were 6 cases of recurrence during the follow-up. ConclusionsHIFU treatment for uterine fibroids is safe and effective, and is an alternative choice for conventional treatment when it is unable to retain the womb or when the patient refuses surgical treatment.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content